User profiles for Marcus Thuresson
 | Marcus ThuressonStatisticon AB Verified email at statisticon.se Cited by 7921 |
Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective
…, M Henriksson, H Hjelm, M Thuresson… - European heart …, 2015 - academic.oup.com
Aims Long-term disease progression following myocardial infarction (MI) is not well understood.
We examined the risk of subsequent cardiovascular events in patients discharged after …
We examined the risk of subsequent cardiovascular events in patients discharged after …
Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study …
Background: Reduction in cardiovascular death and hospitalization for heart failure (HHF)
was recently reported with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) …
was recently reported with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) …
Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study
Background Randomized trials demonstrated a lower risk of cardiovascular (CV) events
with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) …
with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) …
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering …
…, F Persson, HL Gulseth, M Thuresson… - The lancet Diabetes & …, 2017 - thelancet.com
Background In patients with type 2 diabetes and a high cardiovascular risk profile, the
sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been …
sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been …
[HTML][HTML] Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2· 4 million patients from 11 countries: The CaReMe CKD study
…, M Botana, KI Birkeland, M Thuresson… - The Lancet Regional …, 2022 - thelancet.com
Background Digital healthcare systems data could provide insights into the global prevalence
of chronic kidney disease (CKD). We designed the CaReMe CKD study to estimate the …
of chronic kidney disease (CKD). We designed the CaReMe CKD study to estimate the …
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
Background Cardiovascular and kidney outcome trials have shown that sodium-glucose co-transporter-2
(SGLT2) inhibitors slow progression of chronic kidney disease in patients with …
(SGLT2) inhibitors slow progression of chronic kidney disease in patients with …
Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with …
…, HL Gulseth, M Thuresson… - Diabetes, Obesity …, 2018 - Wiley Online Library
Aims To compare the sodium‐glucose‐cotransporter‐2 (SGLT‐2) inhibitor dapagliflozin
with dipeptidyl peptidase‐4 (DPP‐4) inhibitors with regard to risk associations with major …
with dipeptidyl peptidase‐4 (DPP‐4) inhibitors with regard to risk associations with major …
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study
…, A Banerjee, M Thuresson… - Diabetes, obesity …, 2020 - Wiley Online Library
Aims To examine the manifestation of cardiovascular or renal disease (CVRD) in patients
with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated …
with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated …
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)
Aims Use and dosing of guideline‐directed medical therapy (GDMT) in patients with heart
failure (HF) have been shown to be suboptimal. Among new users of GDMT in HF, we …
failure (HF) have been shown to be suboptimal. Among new users of GDMT in HF, we …
Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma
…, JP Laubach, S Thuresson, M Thuresson… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that
targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor …
targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor …